{
    "clinical_study": {
        "@rank": "78794", 
        "arm_group": [
            {
                "arm_group_label": "Doxazosin", 
                "arm_group_type": "Experimental", 
                "description": "doxazosin 4mg/day doxazosin 8mg/day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo control"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine whether doxazosin will attenuate the ability of\n      stress to precipitate smoking lapse behavior in treatment seeking daily smokers.\n      Participants will participate in a smoking cessation attempt after the laboratory sessions."
        }, 
        "brief_title": "Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Smoking", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ages 18-60\n\n          -  Able to read and write English\n\n          -  Smoker\n\n          -  Motivated to Quit Smoking\n\n        Exclusion Criteria:\n\n          -  Any significant current medical conditions that would contraindicate smoking\n\n          -  Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) abuse or\n             dependence of other substances, other than nicotine dependence or alcohol abuse\n\n          -  Positive test results at intake appointment on urine drug screens for illicit drugs\n\n          -  Past 30 day use of psychoactive drugs including anxiolytics and antidepressants\n\n          -  Women who are pregnant or nursing\n\n          -  Suicidal, homicidal or evidence of current severe mental illness such as\n             schizophrenia, bipolar disorder or major depression, or anxiety disorders\n\n          -  Participants who have donated blood within the past 6 weeks\n\n          -  Individuals who are currently taking other medications prescribed for smoking\n             cessation\n\n          -  Specific exclusions for administration of doxazosin or any alpha blocker"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730846", 
            "org_study_id": "1111009293", 
            "secondary_id": "R21DA033597"
        }, 
        "intervention": [
            {
                "arm_group_label": "Doxazosin", 
                "description": "4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study.  5-day taper at the end of the study.\n8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.", 
                "intervention_name": "Doxazosin", 
                "intervention_type": "Drug", 
                "other_name": "Cardura"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Doxazosin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "smoking lapse behavior", 
            "smoking cessation", 
            "doxazosin", 
            "medication effect on smoking lapse behavior", 
            "medication effect on smoking cessation", 
            "stress"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "email": "meaghan.lavery@yale.edu", 
                "last_name": "Meaghan Lavery", 
                "phone": "203-737-2783"
            }, 
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06519"
                }, 
                "name": "Yale Center for Clinical Investigations, Yale University"
            }, 
            "investigator": {
                "last_name": "Sherry A McKee, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?", 
        "overall_contact": {
            "email": "meaghan.lavery@yale.edu", 
            "last_name": "Meaghan Lavery", 
            "phone": "203-737-2783"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Sherry A McKee, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Latency to start smoking (min)", 
            "measure": "Latency (min) to initiate ad-lib smoking session", 
            "safety_issue": "No", 
            "time_frame": "Lab Sessions (Day 20, 22)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730846"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Sherry McKee", 
            "investigator_title": "Associate Professor of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of cigarettes smoking during ad-lib session", 
                "measure": "Number of cigarettes smoked during ad-lib session", 
                "safety_issue": "No", 
                "time_frame": "Lab Sessions (Day 20, 22)"
            }, 
            {
                "description": "Days to first instance of smoking (even a puff)", 
                "measure": "Days to first lapse during quit attempt", 
                "safety_issue": "No", 
                "time_frame": "4-wk smoking cessation attempt"
            }, 
            {
                "description": "Smoking (yes/no) during Week 4 of cessation attempt", 
                "measure": "End of treatment 7-day point prevalence", 
                "safety_issue": "No", 
                "time_frame": "4-wk smoking cessation attempt"
            }
        ], 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}